Cite
HARVARD Citation
Mease, P. et al. (2014). AB0758 Change in Weight from Baseline during the Palace Clinical Trial Program with Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Pooled Results from 3 Phase 3, Randomized, Controlled Trials. Annals of the rheumatic diseases. p. 1055. [Online].